SAN DIEGO - Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology firm currently valued at $74 million, has released interim data from its RIDGE study on arrhythmogenic right ventricular ...

The first-line therapy for arrhythmogenic right ventricular cardiomyopathy (ARVC) is considered to be β-blockers, which are generally well tolerated. However, findings from the Multidisciplinary ...

Differential diagnosis with arrhythmogenic right ventricular cardiomyopathy (ARVC) constitutes a frequent problem, especially in athletes showing ventricular arrhythmias with left bundle branch block ...

The RIDGE-1 Phase 1b clinical trial of TN-401 is currently underway, aiming to enroll up to fifteen adults with PKP2-associated ARVC. Tenaya plans to report safety and biopsy data from the first ...